Literature DB >> 12412832

Marijuana withdrawal syndrome in the animal model.

Aron H Lichtman1, Billy R Martin.   

Abstract

Although the proposition that repeated marijuana use can lead to marijuana dependence has long been accepted, only recently has evidence emerged suggesting that abstinence leads to clinically significant withdrawal symptoms. Converging evidence from human and animal studies has increased our understanding of cannabinoid dependence. One of the most powerful tools to advance this area of research is the CB1 cannabinoid receptor antagonist SR 141716A, which reliably precipitates withdrawal syndromes in mice, rats, and dogs that have been treated repeatedly with cannabinoids. In addition, the use of CB1 receptor knockout mice has revealed that not only cannabinoid dependence is mediated through a CB1 receptor mechanism of action, but CB1 receptors also modulate opioid dependence. Moreover, the results of other genetically altered mouse models suggest the existence of a reciprocal relationship between cannabinoid and opioid systems in drug dependence. Undoubtedly, these animal models will play pivotal roles in further characterizing cannabinoid dependence and elucidating the mechanisms of action, as well as developing potential pharmacotherapies for cannabinoid dependence.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12412832     DOI: 10.1002/j.1552-4604.2002.tb05999.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  33 in total

Review 1.  Animal models of cannabinoid reward.

Authors:  Leigh V Panlilio; Zuzana Justinova; Steven R Goldberg
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

2.  A within-subject comparison of withdrawal symptoms during abstinence from cannabis, tobacco, and both substances.

Authors:  R G Vandrey; A J Budney; J R Hughes; A Liguori
Journal:  Drug Alcohol Depend       Date:  2007-07-23       Impact factor: 4.492

3.  Repeated cannabinoid administration increases indices of noradrenergic activity in rats.

Authors:  M E Page; V C Oropeza; S E Sparks; Y Qian; A S Menko; E J Van Bockstaele
Journal:  Pharmacol Biochem Behav       Date:  2007-01-09       Impact factor: 3.533

4.  DSM-5 cannabis withdrawal syndrome: Demographic and clinical correlates in U.S. adults.

Authors:  Ofir Livne; Dvora Shmulewitz; Shaul Lev-Ran; Deborah S Hasin
Journal:  Drug Alcohol Depend       Date:  2018-10-22       Impact factor: 4.492

Review 5.  A brain on cannabinoids: the role of dopamine release in reward seeking.

Authors:  Erik B Oleson; Joseph F Cheer
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

6.  Drug- and cue-induced reinstatement of cannabinoid-seeking behaviour in male and female rats: influence of ovarian hormones.

Authors:  L Fattore; M S Spano; S Altea; P Fadda; W Fratta
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

7.  Anxiety-like effects of SR141716-precipitated delta9-tetrahydrocannabinol withdrawal in mice in the elevated plus-maze.

Authors:  Peng Huang; Lee-Yuan Liu-Chen; Lynn G Kirby
Journal:  Neurosci Lett       Date:  2010-04-02       Impact factor: 3.046

8.  FAAH-/- mice display differential tolerance, dependence, and cannabinoid receptor adaptation after delta 9-tetrahydrocannabinol and anandamide administration.

Authors:  Katherine W Falenski; Andrew J Thorpe; Joel E Schlosburg; Benjamin F Cravatt; Rehab A Abdullah; Tricia H Smith; Dana E Selley; Aron H Lichtman; Laura J Sim-Selley
Journal:  Neuropsychopharmacology       Date:  2010-03-31       Impact factor: 7.853

9.  Persistent effects of chronic Δ9-THC exposure on motor impulsivity in rats.

Authors:  Cristina Irimia; Ilham Y Polis; David Stouffer; Loren H Parsons
Journal:  Psychopharmacology (Berl)       Date:  2015-04-30       Impact factor: 4.530

10.  The CB receptor agonist WIN 55,212-2 fails to elicit disruption of prepulse inhibition of the startle in Sprague-Dawley rats.

Authors:  Marco Bortolato; Gian Nicola Aru; Roberto Frau; Marco Orrù; Grant Christopher Luckey; Gianluca Boi; Gian Luigi Gessa
Journal:  Psychopharmacology (Berl)       Date:  2004-07-28       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.